Abstract
Aim: To assess the reduction in estimated cardiovascular disease (e-CVD) risk after multifactorial treatment for 6 months and follow this change during the next 3-years. Patients-Methods: This prospective, randomized, target driven study included 1,123 subjects (512/611 men/women, aged 45-65 years) with metabolic syndrome (MetS) without diabetes or CVD referred to specialist outpatient clinics. Patients were randomized to two treatment groups: group A with low density lipoprotein cholesterol (LDL-C) target of > 100 mg/dl and group B with a target of < 130 mg/dl. Atorvastatin was used in both groups on top of optimal multifactorial treatment, (quinapril, amlodipine, hydrochlorothiazide for hypertension, metformin for impaired fasting glucose, and orlistat for obesity). The e-CVD risk was calculated using the Framingham, the PROCAM and Reynolds equations. Results: Reductions in e-CVD risk at 6 months were > 50%in all patients, but were superior in group A and in women. Reductions were even greater during the next 3-years and were mainly attributed to changes in lipid profile. Actual CVD events were 1 in group A and 13 in group B; p=0.0012. Conclusions: Attaining the treatment target of LDL-C < 100 mg/dl within multifactorial treatment of MetS by expert clinics, is achievable and beneficial even in patients without diabetes or known CVD. This induces a considerable e-CVD risk reduction in MetS patients. Actual CVD events were negligible, suggesting that e-CVD risk overestimates actual CVD risk in MetS, at least in patients achieving LDL-C < 100 mg/dl [ClinicalTrials.gov ID: NCT00416741].
Keywords: Metabolic syndrome, cardiovascular disease risk, atorvastatin, multifactorial treatment, Framingham, PROCAM, Reynold's, actual events, obesity, low density lipoprotein cholesterol
Current Vascular Pharmacology
Title: Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women
Volume: 9 Issue: 6
Author(s): Vassilios G. Athyros, Emmanouel Ganotakis, Genovefa D. Kolovou, Vassilios Nicolaou, Apostolos Achimastos, Eleni Bilianou, Theodore Alexandrides, Asterios Karagiannis, Konstantinos Paletas, Evangelos N. Liberopoulos, Konstantinos Tziomalos, Dimitrios Petridis, Anna Kakafika, Moses S. Elisaf and Dimitri P. Mikhailidis
Affiliation:
Keywords: Metabolic syndrome, cardiovascular disease risk, atorvastatin, multifactorial treatment, Framingham, PROCAM, Reynold's, actual events, obesity, low density lipoprotein cholesterol
Abstract: Aim: To assess the reduction in estimated cardiovascular disease (e-CVD) risk after multifactorial treatment for 6 months and follow this change during the next 3-years. Patients-Methods: This prospective, randomized, target driven study included 1,123 subjects (512/611 men/women, aged 45-65 years) with metabolic syndrome (MetS) without diabetes or CVD referred to specialist outpatient clinics. Patients were randomized to two treatment groups: group A with low density lipoprotein cholesterol (LDL-C) target of > 100 mg/dl and group B with a target of < 130 mg/dl. Atorvastatin was used in both groups on top of optimal multifactorial treatment, (quinapril, amlodipine, hydrochlorothiazide for hypertension, metformin for impaired fasting glucose, and orlistat for obesity). The e-CVD risk was calculated using the Framingham, the PROCAM and Reynolds equations. Results: Reductions in e-CVD risk at 6 months were > 50%in all patients, but were superior in group A and in women. Reductions were even greater during the next 3-years and were mainly attributed to changes in lipid profile. Actual CVD events were 1 in group A and 13 in group B; p=0.0012. Conclusions: Attaining the treatment target of LDL-C < 100 mg/dl within multifactorial treatment of MetS by expert clinics, is achievable and beneficial even in patients without diabetes or known CVD. This induces a considerable e-CVD risk reduction in MetS patients. Actual CVD events were negligible, suggesting that e-CVD risk overestimates actual CVD risk in MetS, at least in patients achieving LDL-C < 100 mg/dl [ClinicalTrials.gov ID: NCT00416741].
Export Options
About this article
Cite this article as:
G. Athyros Vassilios, Ganotakis Emmanouel, D. Kolovou Genovefa, Nicolaou Vassilios, Achimastos Apostolos, Bilianou Eleni, Alexandrides Theodore, Karagiannis Asterios, Paletas Konstantinos, N. Liberopoulos Evangelos, Tziomalos Konstantinos, Petridis Dimitrios, Kakafika Anna, S. Elisaf Moses and P. Mikhailidis Dimitri, Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women, Current Vascular Pharmacology 2011; 9 (6) . https://dx.doi.org/10.2174/157016111797484080
DOI https://dx.doi.org/10.2174/157016111797484080 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
How Internet Technology Can Improve the Quality of Care for Substance Use Disorders
Current Drug Abuse Reviews Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Current Drug Targets Apoptogenic Signal Transduction in Arteriosclerosis-Associated Cells – Opportunities for Future Therapy?
Vascular Disease Prevention (Discontinued) Ketamine as Antidepressant? Current State and Future Perspectives
Current Neuropharmacology Synthesis and Biological Activity of 3-(2, 8, 9-Trioxa-aza-1-germatricyclo [3. 3. 3. 0]undecane-1-yl)-hydroxycinnamic Acids
Medicinal Chemistry Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Trypanosomatid Enzymes as Targets for Plant-Derived Compounds: New Perspectives for Phytotherapeutic Approaches
Current Enzyme Inhibition Chronic Cerebral Hypoperfusion Protects Against Acute Focal Ischemia,Improves Motor Function, and Results in Vascular Remodeling
Current Neurovascular Research The Role of Endothelial Progenitor Cells and Statins in Endothelial Function: A Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Influence of Chronic Kidney Disease Development and Renin-angiotensin System Inhibition on Cardiovascular Prognosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Editorial [Hot Topic: Sedation and Analgesia in Post-Anesthesia Intensive Care Unit (Guest Editors: F. Cavaliere and R. Proietti)]
Current Drug Targets Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Editorial [Hot topic: Current Topics in the Development of Radioligands for Positron-Emission Tomography Imaging (Guest Editors: Andrew G. Horti and Robert F. Dannals)]
Current Topics in Medicinal Chemistry Can Group Exercise Programs Improve Health Outcomes in Pregnant Women? A Systematic Review
Current Women`s Health Reviews Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Oxidative Stress, Antioxidants, and Endothelial Function
Current Medicinal Chemistry Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science Patent Selections
Recent Patents on Cardiovascular Drug Discovery Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology